¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

Á¦38Â÷ ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ Ãß°èÇмú½ÉÆ÷Áö¾ö : 2018-11-16

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
Á¦38Â÷ ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ Ãß°èÇмú½ÉÆ÷Áö¾ö : 2018-11-16
±³À°ÀÏÀÚ : 2018-11-16
±³À°Àå¼Ò : °­¸ª¾¾¸¶Å©È£ÅÚ ¾Æ»êÆ®¸®¿ò  
±³À°ÁÖÁ¦ : Á¦38Â÷ ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ Ãß°èÇмú½ÉÆ÷Áö¾ö
ÁÖÃÖ±â°ü : ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ
´ã´çÀÚ : ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ
¿¬¶ôó : 02-794-2630  
À̸ÞÀÏ : webmaster@rheum.or.kr      
±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Á¤Çü¿Ü°ú, Áø´Ü°Ë»çÀÇÇаú      
Âü¼®¿¹»óÀοø : 300¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : °­¿øµµ
±³À°½Ã°£ : 11 ½Ã°£ 40ºÐ  
¼¼ºÎ¼ö°­·á : 60,000¿ø      
ºñ°í : ȸ¿ø Àü¹®ÀÇ, ÀüÀÓÀÇ, ¹Ú»ç±Þ ¿¬±¸¿ø »çÀüµî·Ï 60,000¿ø, ÇöÀåµî·Ï 80,000¿øȸ¿ø Àü°øÀÇ, °£È£»ç, ¼®»ç±Þ ÀÌÇÏ ¿¬±¸¿ø ¿Ü »çÀüµî·Ï 40,000¿ø, ÇöÀåµî·Ï 60,000¿øºñȸ¿ø Àü¹®ÀÇ, ÀüÀÓÀÇ, ¹Ú»ç±Þ ¿¬±¸¿ø »çÀüµî·Ï 80,000¿ø, ÇöÀåµî·Ï 100,000¿øºñȸ¿ø Àü°øÀÇ, °£È£»ç, ¼®»ç±Þ ÀÌÇÏ ¿¬±¸¿ø ¿Ü »çÀüµî·Ï 50,000¿ø, ÇöÀåµî·Ï 70,000¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 09:00~09:30 Validation of FRAX for osteoporosis treatment decision in patients with osteoarthritis: A multicenter comparative study of FRAX criteria and WHO criteria  ±èº¸¿µ(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 09:30~10:00 Angiogenesis using smart material  ±è¼º°ï(°­¸ª¿øÁÖ´ë Ä¡´ë ±¸°­¾Ç¾È¸é¿Ü°úÇÐ) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 10:00~10:30 Ãµ¿¬¹°À» ÀÌ¿ëÇÑ °ñ´Ù°øÁõ Ä¡·áÁ¦ °³¹ß  À¯ÁöÇý(KIST) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 11:00~11:40 Systemic and local fat in knee osteoarthritis.  Changhai Ding(Univ. of Tasmania, Australia) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 11:20~12:00 Management of systemic sclerosis -current status and future directions  Masataka Kuwana(Nippon Medical School, Japan) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 12:10~12:40 ICHOM standard set of outcomes that matter to patients suffering from inflammatory arthritis, explaining the goal of ICHOM, the methodology and how to apply this global development Mart  A.F.J van de Laar(University of Twente, the Netherlands) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 13:30~13:50 What¡¯s the choice after failure of first anti-TNF in RA?  Â÷ÈƼ®(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 13:50~14:10 To taper or not to taper biologics in RA?  ½É½Âö(Ãæ³²ÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 14:10~14:30 Can we stop progression of structural damage in axial SpA?  ±è¿ë±æ(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 14:30~14:50 Do we need to supplement vitamin D in autoimmune rheumatic diseases?  ±è±ÙÅÂ(°í½ÅÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 15:30~15:50 New therapy in SLE: is the glass half-full or half-empty?  ¼­Ã¢Èñ(¾ÆÁÖÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 15:50~16:10 Can we withdraw Immunosuppressants in patients with lupus nephritis in remission?  ¼ºÀ±°æ(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 16:10~16:30 Do we still need biopsy to diagnose Sjögren¡¯s syndrome?  °û½Â±â(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 16:30~16:50 How can we better manage interstitial lung disease in systemic sclerosis?  ÀÌÀººÀ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 09:00~09:30 ÀÓ»óÁø·áÁöħ °³¹ß °³¿ä¿Í ±âȹ  ±èÀç±Ô(Áß¾ÓÀÇ´ë, ´ëÇÑÀÇÇÐȸ Á¤Ã¥ÀÌ»ç) 
±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 09:30~09:50 Áø·áÁöħ °³¹ß °æÇè-GIOP¿Í ¿¹¹æÁ¢Á¾À» Áß½ÉÀ¸·Î  ÀüÂùÈ«(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 09:50~10:05 Áø·áÁöħ °³¹ß Çʿ伺-·ù¸¶Æ¼½º °üÀý¿°  ÀÌÁö¼ö(ÀÌÈ­ÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 10:05~10:20 Ã༺ôÃß°üÀý¿°-°­Á÷ôÃß¿° Ä¡·á±Ç°í °³¹ß  ¹éÇÑÁÖ(°¡ÃµÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 13:30~14:00 Is it possible to prevent RA?  ÀÌ»óÀÏ(°æ»óÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 14:00~14:30 The cellular and molecular mechanisms in cartilage degeneration  Çѽ¿ì(°æºÏÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 14:30~15:00 CAR-T cells beyond cancer: A new therapy for autoimmune diseases?  Á¤ÁØÈ£(¼­¿ïÀÇ´ë »ýÈ­Çб³½Ç) 
±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 15:30~16:00 Epigenetic control of immune cells.  ±è¶ô±Õ(¿¬¼¼ÀÇ´ë ÀÇ»ý¸í°úÇкÎ) 
±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 16:00~16:30 Follicular helper T cell.  ÃÖÀ±¼ö(¼­¿ïÀÇ´ë ÀÇ°úÇаú) 
±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 16:30~17:00 Chronic/persistent infection and autoimmune diseases  ÃÖ¿µ´Ô(¼­¿ïÄ¡Àü¿ø ±¸°­¹Ì»ý¹°Çб³½Ç) 
±³À°½Ã°£ 11-16 Room 3(ÇÏ´ÃȦ, 3F) 13:30~13:50 ·ù¸¶Æ¼½º°üÀý¿°ÀÇ Áúº´È°¼ºµµ ÃøÁ¤.  ÀÌâÈÆ(¿ø±¤ÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 3(ÇÏ´ÃȦ, 3F) 13:50~14:10 °­Á÷ôÃß¿°ÀÇ Áúº´È°¼ºµµ ÃøÁ¤.  ÀÌ»ó¿ø(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 3(ÇÏ´ÃȦ, 3F) 14:10~14:30 °í½ÄÀû ÇÕ¼º Ç×·ù¸¶Æ¼½ºÁ¦Á¦(csDMARDs) ¾Ë¾Æº¸±â  ±èÇö¼÷(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 3(ÇÏ´ÃȦ, 3F) 14:30~14:50 ·ù¸¶Æ¼½º ÁúȯÀÇ Ç¥ÀûÄ¡·áÁ¦.  È«½ÂÀç(°æÈñÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" Á¦38Â÷ ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ Ãß°èÇмú½ÉÆ÷Áö¾ö : 2018-11-16""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 4Â÷»ê¾÷Çõ¸í°ú ³ëÈ­¿¬±¸ÀÇ ¹Ì·¡ (ÀüºÏÀÇ´ë »ýÈ­Çб³½Ç ±èÁ¾¼® ±³¼ö) / °¨¼ºÀ¸·Î ½Î¿ö¶ó -º´¿ø°æ¿µ(¹éâÈñ) : 2018-11-17
´ÙÀ½±Û Ãæ³²´ëÇб³º´¿ø ´ëÀüÁö¿ª¾Ï¼¾ÅÍ È¯ÀÚ¿ì¼±ÀÇ °íÇ°°Ý ¾ÏÁø·á ½ÉÆ÷Áö¾ö : ´ÙÇÐÁ¦ ÅëÇÕÁø·á : 2018-11-16
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
257 ¼­¿ï »ï¼º¼­¿ïº´¿ø 2018 »ï¼º ¾È°ú ±Ý¿äÁý´ãȸ : 2018-09-14 0 678 2018-07-28
256 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø 2018 ÀÇ·áÇöÀå¿¡¼­ ¸¸³ª´Â ¾à¹°¾Ë·¹¸£±â : 2018-09-14 0 833 2018-07-28
255 ¼­¿ï »ï¼º¼­¿ïº´¿ø ¾ÓÄÚ¸£¼­¿ï 2018 : 2018-09-14 0 558 2018-07-28
254 ¼­¿ï ¼­¿ïƯº°½ÃÀÇ»çȸ °­ÀÇ(Àú½ÅÀåÄ¡·á, ¹æ»ç¼±Ä¡·á) : 2018-09-13 0 1,188 2018-07-28
253 ¼­¿ï °í·Á´ëÇб³±¸·Îº´¿ø 1) Á¡¸·Áúȯ 2) ÇǺΠ¸é¿ªÇÐ : 2018-09-13 0 845 2018-07-28
252 ¼­¿ï »ï¼º¼­¿ïº´¿ø ¾ÓÄÚ¸£¼­¿ï 2018 : 2018-09-13 0 468 2018-07-28
251 ºÎ»ê ´ëÇÑ°£ÇÐȸ ºÎ»ê¿ï»ê°æ³²Áöȸ Áý´ãȸ : 2018-09-13 0 612 2018-07-28
250 °æ±â ÇѸ²´ëÇб³¼º½Éº´¿ø ÀӽŠ¹× ¼öÀ¯±â°£ Áß ¾à¹° Ä¡·á : 2018-09-12 0 673 2018-07-28
249 Ãæ³² ´ëÇÑ°¡Á¤ÀÇÇÐȸ °»³â±â È£¸£¸ó Ä¡·áÀÇ ÃÖ½ÅÁö°ß : 2018-09-12 0 615 2018-07-28
248 ¼­¿ï »ï¼º¼­¿ïº´¿ø ¾ÓÄÚ¸£¼­¿ï 2018 : 2018-09-12 0 700 2018-07-28
247 ÀÎõ ÀÎÇÏ´ëÇб³º´¿ø ³ì³»ÀåȯÀÚÀÇ ¾à¹°Ä¡·á : 2018-09-11 0 407 2018-07-28
246 ÃæºÏ 2018³â ÃæºÏ´ëÇб³º´¿ø ºñ´¢ÀÇÇаú ¿¬¼ö°­Á : 2018-09-11 0 675 2018-07-28
245 ¼­¿ï ´ëÇѾȰúÇÐȸ ¼­¿ï ³²ºÎ Áöȸ ¿¬¼ö ±³À° : 2018-09-10 0 712 2018-07-28
244 ¼­¿ï Á¦ 1ȸ °­ºÏ»ï¼ºº´¿ø ¼Ò¾Æû¼Ò³â°ú °³¿øÀÇ ¿¬¼ö°­Á : 2018-09-09 0 768 2018-07-28
243 ¼­¿ï 2018³â ´ëÇѼҾƼÒÈ­±â¿µ¾çÇÐȸ ¼Ò¾Æû¼Ò³â ¿µ¾ç ½ÉÆ÷Áö¾ö : 2018-09-09 0 770 2018-07-28
1391 | 1392 | 1393 | 1394 | 1395 | 1396 | 1397 | 1398 | 1399 | 1400
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷